PPIG and prostate carcinoma: It has two pharmacologically active diastereomers, lower blood-brain barrier permeability, and lacks CYP pathway-mediated effects, it is associated with the fewest grade 3 + adverse events among SGARAs for managing non-metastatic castration-resistant prostate cancer [52,53].